Ignite Creation Date:
2025-12-25 @ 12:13 AM
Ignite Modification Date:
2026-01-05 @ 5:44 PM
Study NCT ID:
NCT05919758
Status:
RECRUITING
Last Update Posted:
2024-07-30
First Post:
2023-05-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001063', 'term': 'Appendiceal Neoplasms'}], 'ancestors': [{'id': 'D002430', 'term': 'Cecal Neoplasms'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D002429', 'term': 'Cecal Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1000}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-05-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-07', 'completionDateStruct': {'date': '2025-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-07-29', 'studyFirstSubmitDate': '2023-05-08', 'studyFirstSubmitQcDate': '2023-06-23', 'lastUpdatePostDateStruct': {'date': '2024-07-30', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-06-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Disease free survival rate', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'defined as alive and free of recurrence of NET at telephone follow-up performed for this study purpose'}, {'measure': 'Recurrence rate', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'defined as histopathologically proven metastasis/residual tumor at appendiceal stump of NET after a disease free period'}], 'secondaryOutcomes': [{'measure': 'Overall survival rate', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'defined as alive at telephone follow-up performed for this study purpose'}, {'measure': 'Complications directly related to primary and secondary treatment divided into major and minor complications according to Clavien-dindo.', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'Complications include, but are not limited to:\n\n* Intra-abdominal abscess, defined as a radiologically confirmed accumulation of purulent fluid in a walled-off space within the abdominal cavity.\n* (Adhesive) bowel obstruction requiring readmission (diagnosis based on clinical signs and symptoms such as a history of constipation, nausea, vomiting and distended abdomen)\n* Superficial Surgical Site Infection, as defined by the CDC criteria. (see table 1.)\n* Deep Surgical Site Infection, as defined by the CDC criteria.'}, {'measure': 'Number of hospital readmission for complications related to treatment of NET', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'see title'}, {'measure': 'Length of hospital stay', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'initial and total length of stay'}, {'measure': 'number of imaging studies performed for follow-up of NET', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), octreotide scintigraphy, PET-CT'}, {'measure': 'Number of outpatient check-ups(regular visits / telephone call) for follow-up of NET', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'see title'}, {'measure': 'Health related Quality of Life at follow-up moment for this study', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'measured by the PedsQL(generic)'}, {'measure': 'Health related Quality of Life at follow-up moment for this study', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'measured by the QLQ-C30(generic)'}, {'measure': 'Health related Quality of Life at follow-up moment for this study', 'timeFrame': 'cross-sectional design. follow-up will be done in 2023/2024', 'description': 'measured by the QLQ-GINET-21 questionnaire(disease specific)'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Neoplasms', 'Appendix Cancer']}, 'descriptionModule': {'briefSummary': 'The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children.\n\n.', 'detailedDescription': 'Aim Current guidelines recommend complementary right-sided hemicolectomy for high-risk (pT2(with risk factors)/pT3) neuro-endocrine tumors (NET) of the appendix (based on adult studies). In contrast to adults, high-risk NET of the appendix in children seems to be a relatively benign disease with high disease-free survival (100% versus 70-80% in adults), but high quality data are lacking. Therefore these recommendations are now being questioned. We aim to investigate the value of complementary right-sided hemicolectomy for children with high-risk NET of the appendix. Ultimately leading to the development of a consensus guideline and solid information for patients/parents.\n\nPlan of investigation In order to generate big data, an international historical cohort study is planned to compare complementary right-sided hemicolectomy with appendectomy alone for children with high-risk NET of the appendix. Results will be CONFIDENTIAL used by an international expert group to formulate treatment recommendations. Subsequently, these recommendations will be tested in an international Delphi study in order to develop a consensus guideline on the treatment of pediatric high-risk NET of the appendix.\n\nExpected results The cohort study will generate high quality information on overall/disease-free survival, recurrence, complications, costs, and hr-QoL. Recommendations made will be tested in a Delphi study; not only on the beneficial value of complementary right-sided hemicolectomy, but also on follow-up protocols and preoperative work-up. Ultimately, an international consensus guideline that redefines low-risk and high-risk NET of the appendix will be developed, leading to global de-escalation and uniformity of treatment.\n\nRelevance for childhood cancer Results are relevant for pediatric oncologists/surgeons/gastro-enterologists across the world, as redefining low-risk and high-risk patient groups, will lead to de-escalation of treatment. Furthermore, QoL of child and parents can be improved by reducing exposure to complications after complementary right-sided hemicolectomy, and by reducing the fear of recurrence by obtaining high-quality data to accurately inform patients and parents.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '17 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'All patients treated for an appendiceal neuro endocrine tumour before the age of 18 during 1990 and 2020', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* All patients that were treated for an appendiceal NET before the age of 18 years old\n* Time period: 1990-2020\n\nExclusion Criteria:\n\n* Other appendiceal malignancies/tumours, for example:\n* goblet cell carcinoma\n* adenocarcinoma\n* neuroendocrine carcinoma'}, 'identificationModule': {'nctId': 'NCT05919758', 'acronym': 'NETkids', 'briefTitle': 'Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix', 'organization': {'class': 'OTHER', 'fullName': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'}, 'officialTitle': 'The Value of Complementary Right-sided Hemicolectomy for Pediatric Patients With High-risk Neuroendocrine Tumors (NETs) of the Appendix; Towards the Development of an (Inter-) National Consensus Guideline for the Pediatric Population.', 'orgStudyIdInfo': {'id': 'W21_169#21.184'}}, 'contactsLocationsModule': {'locations': [{'city': 'Amsterdam-Zuidoost', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Ramon R Gorter', 'role': 'CONTACT', 'email': 'rr.gorter@amsterdamumc.nl'}], 'facility': 'Amsterdam UMC', 'geoPoint': {'lat': 52.3075, 'lon': 4.97222}}], 'centralContacts': [{'name': 'Ramon R Gorter, MD PhD', 'role': 'CONTACT', 'email': 'rr.gorter@amsterdamumc.nl', 'phone': '0205669111'}, {'name': 'Martine F Raphael, MD PhD', 'role': 'CONTACT', 'email': 'm.raphael@amsterdamumc.nl', 'phone': '0205669111'}], 'overallOfficials': [{'name': 'Ramon R Gorter, MD PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Amsterdam UMC, department of pediatric surgery'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'individual participant data will not be shared with other researchers. Collaborating institution will however enter participant data in a coded/pseudonimyzed manner in Castor EDC database.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal investigator', 'investigatorFullName': 'Ramon Gorter', 'investigatorAffiliation': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'}}}}